SecBot SecBot
PRESS-RELEASE ·Filed Mar 19, 2026

BIIB

Biogen Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor the AAD presentation on March 28 for detailed efficacy data, which could drive near-term upside. The Breakthrough Therapy Designation de-risks development and increases probability of approval, supporting long-term valuation upside if Phase 3 confirms results.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$182.88
T+0 close · Mar 19, 2026 · via day close
Latest settled
+8.24%
T+60 · $197.94
Vs SPY
−6.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $182.88entry
  2. T+1 · 8mo ago −1.32%α +0.42% · $180.46
  3. T+5 · 8mo ago +4.14%α +6.36% · $190.46
  4. T+20 · 7mo ago −3.05%α −10.67% · $177.30
  5. T+60 · 5mo ago +8.24%α −6.11% · $197.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen announced upcoming presentation of late-breaking Phase 2 (Part A) results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology meeting. The data supported the FDA's recent Breakthrough Therapy Designation for litifilimab, a potential first-in-class monoclonal antibody targeting BDCA2, highlighting its safety and efficacy in a disease with no approved targeted therapies since the 1950s.

Key Facts

  • Litifilimab received FDA Breakthrough Therapy Designation for CLE based on Phase 2 LILAC and AMETHYST Part A results.
  • Late-breaking 24-week Phase 2 AMETHYST Part A data will be presented at AAD 2026, showing efficacy and safety in CLE.
  • Phase 3 part of AMETHYST is ongoing with data expected in 2027.
  • Litifilimab is a first-in-class anti-BDCA2 monoclonal antibody discovered in-house at Biogen.
  • CLE has no approved targeted therapies; current standard of care dates back to the 1950s.

Financial Impact

High commercial potential given unmet need in CLE and Breakthrough Therapy status, though no revenue impact until 2027 at earliest.

pipeline_valuefuture_revenueR_and_D_value

Risk Factors

  • Phase 3 data may not replicate Phase 2 results.
  • Regulatory approval is not guaranteed despite Breakthrough status.
  • Commercial uptake could be limited by competition or pricing challenges.

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
47% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258886

Track record

34 reports on BIIB

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026